Display options
Cite
Raghunathan V, Sethi SK, Dragon-Durey MA, et al. Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome. Indian J Nephrol. 2017;27(2):136-140doi: 10.4103/0971-4065.181462.
Raghunathan, V., Sethi, S. K., Dragon-Durey, M. A., Dhaliwal, M., Raina, R., Jha, P., Bansal, S. B., & Kher, V. (2017). Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome. Indian journal of nephrology, 27(2), 136-140. https://doi.org/10.4103/0971-4065.181462
Raghunathan, V, et al. "Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome." Indian journal of nephrology vol. 27,2 (2017): 136-140. doi: https://doi.org/10.4103/0971-4065.181462
Raghunathan V, Sethi SK, Dragon-Durey MA, Dhaliwal M, Raina R, Jha P, Bansal SB, Kher V. Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome. Indian J Nephrol. 2017 Mar-Apr;27(2):136-140. doi: 10.4103/0971-4065.181462. PMID: 28356668; PMCID: PMC5358156.
Copy Download .nbib Format: NLM
Share it on

Indian J Nephrol. 2017 Mar-Apr;27(2):136-140. doi: 10.4103/0971-4065.181462.

Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome.

Indian journal of nephrology

V Raghunathan, S K Sethi, M A Dragon-Durey, M Dhaliwal, R Raina, P Jha, S B Bansal, V Kher

Affiliations

  1. Pediatric Critical Care Unit, Medanta - The Medicity, Gurgaon, Haryana, India.
  2. Kidney Institute, Medanta - The Medicity, Gurgaon, Haryana, India.
  3. Department of Immunology, Georges Pompidou European Hospital, APHP, Paris, France.
  4. Department of Pediatric Nephrology, Akron Children's Hospital, Akron, Ohio, USA.

PMID: 28356668 PMCID: PMC5358156 DOI: 10.4103/0971-4065.181462

Abstract

Hypertension is common in hemolytic uremic syndrome (HUS) and often difficult to control. Local renin-angiotensin activation is believed to be an important part of thrombotic microangiopathy, leading to a vicious cycle of progressive renal injury and intractable hypertension. This has been demonstrated

Keywords: Enalapril; enalaprilat; hemolytic uremic syndrome; malignant hypertension; renin

Conflict of interest statement

There are no conflicts of interest.

References

  1. Clin Pharmacol Ther. 1994 Aug;56(2):160-8 - PubMed
  2. Am J Kidney Dis. 1996 Apr;27(4):459-75 - PubMed
  3. Pediatr Nephrol. 2004 Jun;19(6):688-90 - PubMed
  4. Int J Pediatr Nephrol. 1982 Sep;3(3):211-4 - PubMed
  5. Pediatrics. 2004 Aug;114(2 Suppl 4th Report):555-76 - PubMed
  6. J Renin Angiotensin Aldosterone Syst. 2007 Dec;8(4):190-8 - PubMed
  7. Pediatr Nephrol. 1994 Aug;8(4):444-6 - PubMed
  8. Hypertension. 2003 Dec;42(6):1137-43 - PubMed
  9. J Pediatr. 1990 Oct;117(4):664-7 - PubMed
  10. Clin Pediatr (Phila). 2013 Jul;52(7):599-607 - PubMed
  11. J Am Coll Cardiol. 2008 Feb 5;51(5):519-28 - PubMed
  12. J Hum Hypertens. 1997 Mar;11(3):177-83 - PubMed
  13. Pediatr Nephrol. 2008 Feb;23(2):221-31 - PubMed
  14. J Clin Hypertens. 1986 Sep;2(3):245-53 - PubMed
  15. Arch Mal Coeur Vaiss. 1981 Jun;74 Spec No:37-43 - PubMed
  16. Cureus. 2015 Nov 04;7(11):e375 - PubMed
  17. Arch Dis Child. 1974 Oct;49(10):802-7 - PubMed
  18. Pharmacotherapy. 2000 Feb;20(2):140-50 - PubMed

Publication Types